10-Q · May 8, 2026
Ligand Pharmaceuticals posted Q1 2026 results showing revenue of $51.7 million, reflecting a 14% increase year-over-year but below estimates by approximately 12%. Gross margins remain robust at 95%, and the company…
Earnings analysis · 10-Q
LGND earnings analysis
Filed August 7, 2026 · Our reading of the company's report
The latest report
Q2 2026 operating results showed a favorable trend, with revenue of $63.693 million and diluted EPS of $2.37, both materially above Q1 2026 and Q2 2025 levels. The company also completed a $60.0 million share repurchase…
Read full summary
Q2 2026 operating results showed a favorable trend, with revenue of $63.693 million and diluted EPS of $2.37, both materially above Q1 2026 and Q2 2025 levels. The company also completed a $60.0 million share repurchase funded partly by the 2031 Notes offering, while the Nexterone litigation was dismissed without prejudice. However, the filing highlights significant new risks from XOMA integration, obligations under the 2030 and 2031 Notes, royalty buyout provisions and the expanding Viking litigation.
Reported figures
- Earnings per share
- $2.37
What stood out
-
Revenue and EPS improved sharply
Q2 2026 revenue was $63.693 million, up approximately 22% from $52 million in Q1 2026 and approximately 33% from $48 million in Q2 2025. Diluted EPS was $2.37 versus negative $0.67 in Q1 2026 and $0.24 in Q2 2025.
-
Share repurchase supported by note proceeds
The company repurchased 228,859 shares at $262.17 per share in June 2026, using approximately $60.0 million of net proceeds from the 2031 Notes offering and cash on hand.
-
New 2031 convertible financing
The company issued 0.00% Convertible Senior Notes due 2031, adding a new financing source alongside its 2030 Notes and supporting liquidity for strategic activity.
-
Nexterone litigation concluded
In the Captisol-enabled Nexterone litigation, the parties submitted a joint dismissal stipulation on June 16, 2026, and the court entered the dismissal without prejudice on July 23, 2026.
-
CyDex secured partial pleadings ruling
The Delaware court denied Bexson’s motion for judgment on the pleadings and granted part of CyDex’s motion on April 22, 2026; the matter is expected to proceed to discovery.
What to watch
-
Viking cross-complaint adds litigation exposure
Ligand’s Viking dispute expanded after Viking filed a cross-complaint on July 2, 2026 asserting 3 causes of action, including declaratory relief and breach of contract. Ligand states that the matter is at an early stage and that potential losses cannot be estimated.
-
XOMA integration execution risk
The company added an XOMA Acquisition integration risk, stating that integration of operations, personnel, systems and the royalty portfolio could be more costly or time-consuming than anticipated and could materially adversely affect results and cash flows.
-
Debt service and refinancing risk
The company added a debt-servicing risk covering its 2030 Notes and 2031 Notes, including potential cash repurchases upon specified events and possible dilution if the notes convert. The filing also states that insufficient operating cash flow could require asset sales, debt restructuring or additional equity or debt financing.
-
Royalty buyout rights may reduce revenue
Certain royalty and milestone arrangements permit counterparties to reduce, buy down or buy out future obligations for predetermined amounts that may be less than the net present value of future royalties, potentially reducing recurring revenue.
Management's outlook
The supplied 10-Q text does not include a quantitative outlook. Prior company guidance was reported separately as revenue of $270 million-$310 million and EPS of $8.50-$9.50, but no confirmation or change is provided in the supplied filing excerpt.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.